TD Cowen Raises Tandem Diabetes Price Target, Maintains Buy Rating

TD Cowen has increased its price target for Tandem Diabetes (TNDM) while reiterating its 'Buy' rating for the company. This indicates a continued positive outlook on the medical device firm.